Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient‐derived osteosarcoma cells and synergizes with cisplatin and talazoparibChristopher L. Heidler, Andreas E. Kulozik|International Journal of Cancer|2019Cited by 26